Table 3.
Clinical and pathological data of diffuse gliomas with KIAA1549Ex16‐BRAFEx9 fusion gene and their association with IDH mutations and/or 1p/19q loss. Abbreviations: A = astrocytoma; GBM = glioblastoma; IDH = isocitrate dehydrogenase; Mut = mutant; NA = not analyzed; OA = oligoastrocytoma; OO = oligodendroglioma; WHO = World Health Organization; WT = wild type.
| Case | Sex | Age (years) | Diagnosis* | Location | KIAA1549 Ex16‐ BRAF Ex9 | IDH1 fusion | IDH2 | 1p19q loss | Follow‐up (months) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Female | 52 | GBM | Insular | Yes | WT | NA | NA | 8 (dead) |
| 2 | Male | 50 | OOII | Temporal | Yes | Mut† | NA | Yes | 72 (alive) |
| 3 | Female | 32 | OA II | Parietal | Yes | Mut† | NA | Yes | 70 (alive) |
| 4 | Male | 45 | OO III | Frontal | Yes | Mut† | NA | NA | 70 (alive) |
| 5 | Female | 50 | OO III | Multifocal | Yes | Mut† | NA | Yes | 48 (alive) |
| 6 | Female | 35 | OA II | Frontal | Yes | Mut† | NA | Yes | 47 (alive) |
| 7 | Male | 34 | OO II | Frontal | Yes | Mut† | NA | Yes | 36 (alive) |
| 8 | Female | 53 | OO III | Frontal | Yes | NA | NA | NA | 24 (dead) |
| 9 | Female | 33 | OA III | Hemispheric | Yes | Mut† | WT | No | 45 (alive) |
| 10 | Female | 32 | A II | Hemispheric | Yes | Mut† | WT | No | 48 (dead) |
| 11 | Female | 53 | OO II | Hemispheric | Yes | Mut† | WT | No | 21 (alive) |
| 12 | Male | 46 | OO II | Hemispheric | Yes | Mut† | WT | Yes | 29 (alive) |
| 13 | Female | 43 | OO III | Hemispheric | Yes | WT | Mut‡ | No | 19 (dead) |
| 14 | Male | 44 | OO III | Frontal | Yes | WT | WT | No | 16 (dead) |
| 15 | Male | 43 | OO III | Temporal‐occipital | Yes | WT | WT | No | 26 (dead) |
| 16 | Male | 41 | OO III | Temporal | Yes | WT | WT | No | 13 (alive) |
| 17 | Female | 73 | OO III | Hemispheric | Yes | WT | WT | No | 46 (dead) |
Roman numerals refer to WHO histological grade.
IDH1R132H
IDH2R172K